FDA Regulatory Status and Safety Update for Peptides

Clinical Question

How have recent FDA regulatory actions, compounding classifications, and post-marketing safety signals changed the clinical landscape for peptide therapy as of late 2026?

Evidence Snapshot

Semaglutide: FDA-approved (Ozempic, Wegovy, Rybelsus); shortage-related compounding discretion has ended.
BPC-157: FDA Category 2 status; reviewed by Pharmacy Compounding Advisory Committee (PCAC) in July 2026.
GHRP-2/GHRP-6: 503B Category 2 (Sept 2023) due to immunogenicity concerns.
Melanotan II: 503A Category 2 (Sept 2023) following serious adverse events.
Safety Signals: Emerging signals for semaglutide include NAION (under EMA review) and pulmonary aspiration (added to label 2025).
Clinical Trials: Phase III weight loss data shows 14.9% for semaglutide (STEP 1) and 22.5% for tirzepatide (SURMOUNT-1).

What the Research Shows

Regulatory Updates and Compounding Status

As of September 2026, the regulatory status for several widely discussed peptides has undergone significant shifts. Semaglutide is FDA-approved for indications including type 2 diabetes and chronic weight management. The FDA has clarified that national shortage-related compounding enforcement discretion has ended. Patient-specific compounding remains subject to Section 503A, including restrictions on compounding drugs that are essentially copies of commercially available products. Furthermore, the FDA has proposed excluding semaglutide from the 503B Bulks List due to a lack of identified clinical need.

BPC-157 and KPV were reviewed by the Pharmacy Compounding Advisory Committee (PCAC) in July 2026 for possible inclusion on the 503A Bulks List. BPC-157 was previously placed in FDA Category 2, with the agency identifying concerns regarding immunogenicity, peptide-related impurities, and limited human safety information. KPV also underwent PCAC review after a previous nomination withdrawal.

Other agents have been restricted due to safety concerns. GHRP-2 and GHRP-6 were placed in 503B Category 2 in September 2023, specifically citing immunogenicity risks. Melanotan II is listed as 503A Category 2 following multiple serious adverse events and safety warnings from the FDA and TGA. LL-37 is also categorized under 503A Category 2 due to safety concerns.

Safety Signals and Adverse Events

Post-marketing surveillance via FAERS has identified several signals for semaglutide. While nausea and vomiting remain strong, expected signals listed in the label (Section 6), newer signals have emerged. These include intestinal obstruction (ileus) and pulmonary aspiration, the latter of which was added to the Ozempic label in 2025 due to risks during general anesthesia associated with delayed gastric emptying.

Notably, Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) is an emerging signal with 96 cases reported through December 2024, prompting a formal review by the EMA in January 2025. Suicidal ideation remains under evaluation; current data do not support a higher risk compared to background rates, though the FDA requires ongoing monitoring.

Clinical Trial Outcomes

Phase III data for GLP-1 and dual/triple agonists demonstrate significant weight loss efficacy. The STEP 1 trial (NCT03548935) reported 14.9% weight loss for semaglutide, while the SURMOUNT-1 trial (NCT04184622) reported 22.5% weight loss for tirzepatide. In the SURMOUNT-5 head-to-head trial, tirzepatide was found superior to semaglutide. Retatrutide, currently in Phase III (TRIUMPH-3), showed 24.2% weight loss at a 12mg dose in Phase II trials.

In other peptide research, the Phase III TESTS trial for Thymosin Alpha 1 in sepsis (NCT02867267) yielded negative results, showing no reduction in mortality. Tesamorelin demonstrated an 18% reduction in visceral adipose tissue (VAT) in its pivotal Phase III trial for HIV lipodystrophy.

Mechanism

The provided data does not contain mechanistic details for these compounds beyond their classification as peptides or non-peptide GH secretagogues (in the case of MK-677).

Limitations of the Evidence

The FDA has explicitly noted a lack of human safety data for several compounds, including BPC-157 and KPV. The status of many peptides remains in "Category 2," indicating the FDA has identified significant safety risks or a lack of data to support their use in routine compounding. For semaglutide, emerging signals like NAION and pulmonary aspiration require further longitudinal data to fully characterize the absolute risk. Additionally, the FDA has noted that salt forms (semaglutide sodium and acetate) lack a lawful basis for use in compounding as they differ from the active ingredients in approved products.

Clinical Takeaway

Physicians should be aware that the regulatory landscape for compounded peptides is tightening, with several agents (BPC-157, GHRP-2, Melanotan II) facing Category 2 restrictions due to immunogenicity or adverse event profiles. While semaglutide and tirzepatide show high efficacy in Phase III trials, new safety signals regarding NAION and anesthesia-related aspiration have been integrated into regulatory monitoring and labeling as of 2025-2026.

Sources

FDA: Certain bulk drug substances that may present significant safety risks.
FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.
FDA: Clarification on policies for compounders as national GLP-1 supply stabilizes.
PMID: 33567185 (STEP 1), PMID: 35658024 (SURMOUNT-1), PMID: 39814420 (Thymosin Alpha 1 sepsis trial).
FAERS Data 2023-2025 (Safety signals for semaglutide).

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice. Physicians interested in integrating evidence-based therapies can learn how to find a peptide prescriber through our verified network. To locate qualified facilities, please visit our directory for peptide therapy near me.